Bloomberg News reported on Tuesday that the two companies were looking at taking over Teleflex. Reuters published that the offer is said to be under evaluation by the medical device firm, but the source emphasized that no deal is guaranteed. This leaves room for Teleflex to reject the proposal or attract competing bids.
Medtech is swinging private again – and that matters for startup M&A.
Teleflex specializes in products such as breathing tubes, catheters, and vascular access devices commonly used in hospital intensive care units. The company has been undergoing a strategic transformation – including the sale of three business units for $2.03 billion in December 2025 – as part of its efforts to streamline operations and focus on core areas.
“Medtech is swinging private again – and that matters for startup M&A,” Barak Singer, executive VP, head of Healthcare, The Trendlines Group, posted on LinkedIn. “This shift isn’t just a capital‑markets story. It directly shapes how large medtech platforms buy innovation.”
Singer described how we have witnessed this cycle before with Medline and noted that it “spent years building under private ownership before returning to public markets at scale.” He concluded by stating that “as more large medtech players move (or prepare to move) private, the environment for strategic M&A into startups improves meaningfully – more flexibility, more patience, and more willingness to buy ahead of full de‑risking.”
Reuters described how the potential acquisition comes at a time when Teleflex has faced mounting pressure from activist investor Irenic Capital Management. In March, Irenic criticized the company’s board for its reluctance to engage with potential buyers, urging a more open approach to exploring strategic alternatives.
If the supposed deal is successful, it would take the publicly traded company private. This could provide Teleflex with the flexibility to execute its strategic overhaul away from the scrutiny of public markets.
The details of the bid remain under wraps. Neither CVC, GTCR, nor Teleflex have commented on the matter. For now, all eyes will remain on Teleflex as it weighs its options, with the possibility of rival bids adding further intrigue to the unfolding story.
Teleflex shares surged 13.4% in after-hours trading following the news.